Top

Scientific Programme


All times are CET

WEDNESDAY OCTOBER 27 2021

14:00-14:30    Welcome and introduction
  • R. de Franchis (Milan, Italy)
  • Tribute to the Baveno Legends
  • Tom Boyer
  • Andy Burroughs
  • Roberto Groszmann
  • Luigi Pagliaro
14:30-15:15    INTRODUCTORY LECTURES

  • Chairpersons: J. Bosch (Bern, Switzerland), R. de Franchis (Milan, Italy), G. Garcia-Tsao (New Haven, USA)
    LECTURE-1: New concept of risk stratification
    J.G. Abraldes (Edmonton, Canada)
    LECTURE-2: Clinical stages and ordinal outcomes in portal hypertension
    G. D’Amico (Palermo, Italy)
    LECTURE-3: Lifestyle and genetic modifiers of liver disease progression
    A. Berzigotti (Bern, Switzerland)
15.15-15.30    Break


WEDNESDAY OCTOBER 27 2021

15.30-18.30    SESSION 1

  • EVALUATION AND RISK STRATIFICATION
15.30-16-15   Part 1: HVPG as a gold standard
  • Chairpersons: J.C. Garcia-Pagàn (Barcelona), Z. Haskal (Charlotteville)
    Panelists: F. Schepis (Modena), R. Gaba (Chicago), H. Ferral (Evanston)
    • Quality Metrics in HVPG and Porto-Systemic Pressure Gradient (PPG)
    • Usefulness of HVPG in:
      • the diagnosis of CSPH in cirrhosis of different etiologies
      • assessing the response to vasoactive drugs for risk stratification of variceal (re-)bleeding
      • assessing the prognosis of patients with cirrhosis
      • clinical trials vs. proof of concept studies
    • PPG in the setting of TIPS
    • Consensus statements
16.15-16.30    Break


16.30-18.30   Part 2: Noninvasive tools for cACLD and portal hypertension
  • Chairpersons: A. Berzigotti (Bern), J. Genescà (Barcelona)
    Panelists: J.G. Abraldes (Edmonton, Canada), J. Fallowfield (Edinburgh, United Kingdom), M. Thiele (Odense, Denmark)
    • cACLD and CSPH
    • Detection of varices with noninvasive tools and screening endoscopy
    • Use of noninvasive tools for prognosis in cirrhosis
    • Spleen stiffness
    • Emerging non-invasive markers: imaging, blood and liver clearance tests
    • Proposed consensus statements
End of the Day


THURSDAY OCTOBER 28 2021

14:00-14:30    Presentation of selected abstracts

14:00-17:30    Session 2

  • NEW SCENARIOS
14.30-15.15   Part 1: Progression and regression of cirrhosis
  • Chairpersons: W. Laleman (Leuven), D. Patch (London)
    LECTURE-4: PELS in progression. Can they regress?
    I. Wanless (Halifax)
    LECTURE-5: Fibrogenesis and regression of fibrosis
    M. Pinzani (London
    LECTURE-6: Angiogenesis and progression of ACLD
    V. Shah (Rochester)
15.15-15.30    Break

  • LECTURE-7: Drugs to modify liver fibrosis progression and regression (preclinical and clinical studies
    J. Gracia (Barcelona)

15.45-16.30   Part 2: Impact of etiological therapies in the course of cirrhosis
  • Chairpersons: M. Mandorfer (Vienna, Austria), E. Tsochatzis (London, United Kingdom)
    Panelists: S. Francque (Antwerp, Belgium), J. Jia (Bejing, China), S. Lens (Barcelona, Spain), H. Yoshiji (Kashihara, Japan
    • Impact of etiological therapies on disease progression vs. regression in
      • Alcohol-related liver disease
      • Non-alcoholic fatty liver disease
      • Hepatitis B
      • Hepatitis C
    • Presentation of recommendations for the management of cirrhosis after control of the primary etiological factor
16.30-16.45    Break

16.45-17.30   Part 3: Impact of non-etiological therapies in the course of cirrhosis
  • Chairpersons: A. Albillos (Madrid), J. Trebicka (Frankfurt)
    Panelists: J. Bajaj (Richmond), J. Gracia (Barcelona), A. Krag (Odense), W. Laleman (Leuven), V. Shah (Rochester)

    • Impact of drugs acting on the gut/microbiome
    • Impact of statins and FXR/PPAR agonists in the treatment of patients with cirrhosis and portal hypertension
    • Use of anticoagulants (LMWH, DOAC) and antiplatelet drugs (ASS) in the management of cirrhosis and portal hypertension
    • Proposed consensus statements
17.30-17.45    Break

17.45-19.00    Session 3

  • CLINICAL SETTINGS
17.45-19.00   Part 1: Preventing (first) decompensation. Review of current evidence
  • Chairpersons: J. Bosch (Bern), C. Ripoll (Halle)
    Panelists: V. Calvaruso (Palermo), R. Bañares (Madrid), S. Gomes Rodrigues (Bern), A. Dell’Era (Milan), C. Villanueva (Barcelona), D. Tripathi (Birmingham)
    • Results of the questionnaire
    • Definition of decompensation:
      • Systematic review of studies that evaluate the natural history of cirrhosis and their definition of decompensation
      • The role of jaundice, perihepatic ascites, MHE and bleeding due to portal hypertensive gastropathy in the definition of decompensation
      • Impact of the sole presence of infection and of sarcopenia (without other manifestations of decompensation) in the natural history of compensated cirrhosis
    • Use of NSBB in prevention of (first) decompensation:
      • Specific evaluation of the effect of CSPH, reduction of HVPG and other predictive factors
      • Meta-analysis with individual patient data on the effects of Carvedilol in the prevention of first decompensation
    • Proposed Consensus Statements: Prevention of first decompensation
End of the Day


FRIDAY OCTOBER 29 2021

14:00-14:30    Presentation of selected abstracts

14:30-15:30   INDUSTRY SPONSORED SYMPOSIUM

15.30-15.45    Break
15.45-18.15    Session 3

  • CLINICAL SETTINGS (CONTINUED)
15.45-16.45   Part 2: Acute variceal bleeding
  • Chairpersons: D. Thabut (Paris), V. Hernández-Gea (Barcelona)
    Panelists: D. Patch (London), A. Cárdenas (Barcelona), A. Escorsell (Barcelona), M. Rudler (Paris), B. Procopet (Cluj-Napoca), X. Luo (Chengdu), G. Han (Xi’An)

    • Patient Risk stratification and prognostic factors
    • Novelties in general management of Acute Variceal Bleeding (AVB)
    • Endoscopic management: classic and new therapies
    • Pre-emptive TIPS
    • Management of refractory bleeding
    • Proposed consensus statements


16.45-17:00    Break


17.00-18.15   Part 3: Preventing further decompensation. Review of current evidence
  • Chairpersons: G. Garcia-Tsao (New Haven), T. Reiberger (Vienna)
    Panelists: C. Bureau (Toulouse), G. D’Amico (Palermo), V. La Mura (Milan), S. Piano (Padua), P. Tandon (Edmonton), L. Turco (Modena)

    • Clinical concept of further decompensation: outcomes and risk stratification
      • Mortality per type of initial event (ascites, variceal hemorrhage)
      • Further decompensation per type of initial event (VH or/and ascites)
    • Prevention of further decompensation
      • Prevention of rebleeding and other further decompensating events
      • Should NSBB be used in patients with ascites for the prevention of further decompensation?
      • Readdress use of NSBB in patients with refractory ascites
      • TIPS - redefining candidates
    • Sarcopenia and frailty. Exploring its relationship with further decompensation
    • Concept of cirrhosis re-compensation
End of the Day


SATURDAY OCTOBER 30 2021

14:00-15:00   INDUSTRY SPONSORED SYMPOSIUM

15.15-16:30    Break


Session 4

  • VASCULAR LIVER DISORDERS
15.15-16.30   Part 1: SPLANCHNIC VEIN THROMBOSIS
  • Chairpersons: D. Valla (Clichy), S. Sarin (New Delhi)
    Panelists: F. Turon (Barcelona), M. Barrufet (Barcelona), J.J. Kiladjian (Paris), A. Plessier (Clichy), M. Primignani (Milan), A. Baiges (Barcelona)

    • Portal vein thrombosis. Anticoagulation vs Interventional radiology
    • Staging of portal vein thrombosis. Recurrent thrombosis and prognostic factors for recurrence
    • Myeloproliferative neoplasia and splanchnic vein thrombosis: Diagnosis and management
16.30-16.45    Break


16.45-18.00   Part 2: OTHER ISSUES IN VASCULAR LIVER DISORDERS
  • Chairpersons: A. de Gottardi (Lugano), P.E. Rautou (Paris)
    Panelists: S. Murad (Rotterdam), V. Paradis (Clichy), M. Senzolo (Padua), L. Tellez (Madrid)

    • Anticoagulation (including DOACS) in cirrhotic and non-cirrhotic patients
    • Portosinusoidal vascular disease/Idiopathic portal hypertension/noncirrhotic portal hypertension: refining diagnostic criteria including histological criteria
    • Presentation of Consensus Statements (both part 1 and 2)
18.00-18.15    Break



18.15-18.45    DIGITAL BAVENO VII MEETING WRAP UP

  • R. de Franchis (Milan, Italy)
  • G. Garcia-Tsao (New Haven, Usa)
  • J. Bosch (Bern, Switzerland)

End of the Day